Skip to the rundown
GetYourBrief Biotech desk · March 20, 2026
Search

Rundown · Friday, March 20, 2026

Biotech news on March 20, 2026

On Friday, March 20, 2026 the Biotech desk recorded 4 news events. The earliest report came from en.prnasia.com at 03:17 UTC. 2 more events were reported; they are listed at the end.

  1. 01

    MGI Tech and NUS Partner to Launch Multi-Omics DCS Lab in Singapore

    2 outlets · first: en.prnasia.com Pharma

    Machine summary MGI Tech and the National University of Singapore (NUS) have announced a strategic collaboration to establish a DCS Lab focused on multi-omics innovation.

    Reported by en.prnasia.com and manilatimes.net.

    • Multi-omics
    • NUS Pharmacy and Pharmaceutical Sciences
    • MGI Tech
    • DCS Lab

  2. 02

    FluxMateria launches physics-based screening platform

    2 outlets · first: weeklyvoice.com Pharma Mostly press releases

    Machine summary FluxMateria launched a physics-based screening platform that it says is 3.6 million times faster than DFT and does not use AI, according to weeklyvoice.com and palmbeachpost.com.

    Reported by weeklyvoice.com and palmbeachpost.com.

    • DFT (Density Functional Theory)
    • FluxMateria

    Full coverage: every report, when each was published, and who was named (2 outlets)

  3. 03

    iBio says it targets Q3 for lead bispecific candidate in PH-HFpEF treatment

    1 outlet · first: finance.yahoo.com Clinical trial

    Machine summary Key facts from the reports:

    1. iBio said it expects to name a formal development candidate for PH-HFpEF by Q3 2026.

    Reported by finance.yahoo.com.

    • PH-HFpEF
    • iBio
    • Bispecific Antibody

  4. 04

    Invenomic Capital exits $24M Haemonetics stake

    1 outlet · first: fool.com Pharma

    Machine summary Invenomic Capital Management has fully liquidated its $24.29 million position in Haemonetics Corporation.

    1. Invenomic Capital Management sold 498,317 shares of Haemonetics (HAE), valued at $24.29 million.
    2. The exit reduced HAE from 1.2% of the fund's 13F AUM to zero.
    3. Haemonetics shares fell 9% over the past year, while the S&P 500 gained 16%.
    4. Viatris (VTRS) has emerged as the fund's top holding with a $69.64 million position.
    5. Haemonetics' stock price was recorded at $58.58 at the time of the reporting.

    Reported by fool.com.

    • Viatris
    • Invenomic Capital Management
    • Haemonetics Corporation

More events reported

No summary of ours and no outlet headline passed our automated checks for these, which says nothing about the events (how they work); the outlets and their reports are linked.

  1. · 2 outletsyahoo.com, edition.cnn.com
  2. · 2 outletsshanghainews.net (Big News Network), tucsonpost.com (Big News Network)

Each summary and its key facts are a machine summary of the reports linked under it; the outlets, times and counts come from those reports' own records. How a rundown is built.

Also covered for this desk

9 events homed on another desk that the Biotech desk also carried on March 20, 2026.

  1. Mar 20 · Legal Federal Court Blocks RFK Jr. Vaccine Agenda Amid Regulatory Battle 6
  2. Mar 20 · Healthcare Bloomberg: “Novartis to Buy Breast Cancer Drug for as Much as $3 Billion” 3
  3. Mar 20 · Healthcare AeroDel enters exclusive licensing agreement with Zydus to launch Aerolife Mini 2
  4. Mar 20 · Healthcare seekingalpha.com: “Relmada Therapeutics, Inc. (RLMD) Q4 2025 Earnings Call Transcript” 2
  5. Mar 20 · Healthcare Antengene announces 2025 full-year results 1
  6. Mar 20 · Healthcare Peptide supplier shuts down operations, Nova Life Peptides says 1

The days around it

Sources: the outlets' reports linked on this page; counts and times from GetYourBrief's record of those reports (methodology).